Clinical Trial Finder

• Restore CFTR FunctionEnrolling

  Phase 1 study of PTI-808 drug and triple combination in healthy adults and then in adults with cystic fibrosis , protocol number Proteostasis PTI-808-01

  Parts 1 and 2 of this study will take place in healthy volunteers. Part 3 of this study is taking place in adults with cystic fibrosis at multiple care centers across the U.S. It will look at the safety, tolerability, and how the body processes the drug in multiple ascending doses of PTI-808 and PTI-808 together with PTI-428 and PTI-801.

  • Age:

    18 Years and Older

  • Mutation(s):

    Two Copies F508del

  • FEV1% Predicted:

    40 to 90%

  • Number of Visits:

    10

  • Length of Participation:

    56 days

• Mucociliary ClearanceEnrolling

  SHIP CT: Study of hypertonic saline in preschoolers , protocol number SHIP002

  This study is taking place in Europe, Australia and the U.S. It will look at the safety and effectiveness of hypertonic saline compared to isotonic saline (normal saline) in children with CF.

  • Age:

    3 Years to 5 Years

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    6

  • Length of Participation:

    54 weeks

• Anti-InflammatoryEnrolling

  Phase 2 study of LAU-7b in adults with CF (APPLAUD) , protocol number Laurent LAU-14-01

  This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the anti-inflammatory drug LAU-7b and will use a placebo control.

  • Age:

    12 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    50 to 90%

  • Number of Visits:

    6

  • Length of Participation:

    189 days

• Anti-InfectiveEnrolling

  TEACH: Testing the effect of adding oral azithromycin to inhaled tobramycin in people with CF , protocol number TEACH-IP-15

  This phase 2 study is taking place at multiple care centers across the U.S. It will look at the effect of adding oral azithromycin to inhaled tobramycin and will use a placebo control.

  • Age:

    12 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    25 to 100%

  • Number of Visits:

    5

  • Length of Participation:

    14 weeks

• ObservationalEnrolling

  Rare mutation cell collection (RARE) , protocol number RARE-OB-16

  This study is taking place at multiple care centers across the U.S. Researchers will collect and make available for study cells from people with rare CFTR mutations.

  • Age:

    2 Years and Older

  • Mutation(s):

    No Copies F508del

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    1

  • Length of Participation:

    1 days

Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.